Compound W

CAS No. 173550-33-9

Compound W( —— )

Catalog No. M23782 CAS No. 173550-33-9

The compound is an inhibitor of γ-secretase. It also causes a decrease in the released levels of Aβ42 and notch-1 Aβ-like peptide 25 (Nβ25).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 39 In Stock
50MG 61 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Compound W
  • Note
    Research use only, not for human use.
  • Brief Description
    The compound is an inhibitor of γ-secretase. It also causes a decrease in the released levels of Aβ42 and notch-1 Aβ-like peptide 25 (Nβ25).
  • Description
    The compound is an inhibitor of γ-secretase. It also causes a decrease in the released levels of Aβ42 and notch-1 Aβ-like peptide 25 (Nβ25).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Neuroscience
  • Target
    Gamma-secretase
  • Recptor
    γ secretase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    173550-33-9
  • Formula Weight
    396.31
  • Molecular Formula
    C19H12N2O8
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:<39.63mg/mL;1.1eq. NaOH:<19.81mg/mL
  • SMILES
    [O-][N+](c(cc1)ccc1Oc1cc(C(O)=O)cc(Oc(cc2)ccc2[N+]([O-])=O)c1)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Jagged-1 188-204

    This peptide is a fragment of the JAG-1 protein. JAG-1 is Notch ligand, a peptide that is the most conspicuously expressed ligand in skin. JAG-1 induces epidermal maturation. Exposing submerged keratinocytes monolayers to JAG-1 with elevated calcium concentration produces stratification with loricrin expression and NF-αB activation.

  • Demcizumab

    Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody and a potent Notch pathway inhibitor, demonstrating efficacy in various cancer models both as a monotherapy and in conjunction with chemotherapy agents.

  • Enoticumab

    Enoticumab (REGN421) is a fully human IgG1 monoclonal antibody with anticancer activity that inhibits the growth of cancer cells.Enoticumab binds human Dll4 and disrupts Notch-mediated signaling.